<DOC>
	<DOCNO>NCT01868269</DOCNO>
	<brief_summary>The OMS/DES study multinational European Trial Children Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome . This trial bring way specialist EPNS ( European Paediatric Neurology Society ) , GPOH ( Gesellschaft für Pädiatrische Hematologic und Oncologie ) SIOPEN ( SIOP ( International Society Oncology Pediatric ) Europe Neuroblastoma ) . This protocol investigate escalate treatment schedule start corticosteroid standard treatment dexamethasone pulse ( first step ) , follow , response inadequate 3 month treatment , addition CP ( second step ) , still sufficient improvement , replacement CP Rituximab ( third step ) . Treatment intensification decide basis standardize score OMS/DES severity .</brief_summary>
	<brief_title>Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome ( OMS/DES ) Children With Without Neuroblastoma ( NBpos NBneg ) Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome ( OMS/DES ) Children With Without Neuroblastoma ( NBpos NBneg )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Myoclonus</mesh_term>
	<mesh_term>Ocular Motility Disorders</mesh_term>
	<mesh_term>Opsoclonus-Myoclonus Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Children newly diagnose OMS/DES either NBpos NBneg . Three follow four component necessary diagnosis OMS/DES : Opsoclonus ocular flutter ( nystagmus ) Ataxia and/or myoclonus Behavioural change and/or sleep disturbance Neuroblastoma The diagnosis OMS/DES may difficult patient . Opsoclonus , particular , may intermittent late onset . A video example available www.dancingeyes.org.uk . If uncertain , please contact national coordinator support interpret clinical feature . Age 6 month le 8 year ( &lt; 8th birthday ) The date diagnosis OMS/DES date doctor confirm condition OMS/DES . The date symptom onset need also document . Treatment start standard corticosteroid treatment dexamethasone pulse propose guideline give trial protocol ( see 11.10 , page 71 ) . In patient presumed NBneg OMS/DES , neuroblastoma must exclude accord guideline trial ( see chapter 4.4.1.4 , page 30 , appendix 11.9 , page 70 ) Documented informed consent treatment enrolment trial parent / legal representative . •Patients opsoclonus , myoclonus ataxia cause identified disease ( e.g . current active CNS infection , neurometabolic disorder demyelination ) . An identified viral precursor exclusion criterion . prior parallel use chemotherapy ( require treatment neuroblastoma ) Corticoid steroid OMS/DES reason last 14 day immediately treatment start accord standard treatment propose ( treatment corticosteroid less 14 day allow ) contreindication use one experimental study drug ( cf Summary Product Characteristics use study )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>